Every material Form 8-K iRhythm Holdings, Inc. has filed with the SEC since September 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
iRhythm reported third-quarter 2026 revenue of $221.6 million, up 14.9% from a year earlier, and raised its full-year 2026 revenue guidance to $890 million to $895 million. The GAAP net loss widened to $29.9 million, or $0.90 per share, from $5.2 million, or $0.16 per share, a year earlier, and the quarter included $49.8 million in litigation settlement charges.
Q3 2026 revenue of $221.6 million, up from $192.9 million in Q3 2025; gross margin was 74.2%
GAAP net loss of $29.9 million, or $0.90 per diluted share, versus a net loss of $5.2 million, or $0.16 per share, in Q3 2025
Litigation settlements of $49.8 million were recorded in the quarter
2026 revenue guidance raised to $890 million to $895 million, including about $16 million from the VitalConnect acquisition closed October 5, 2026
iRhythm Holdings said on October 5, 2026 that it completed its previously announced acquisition of VitalConnect, a maker of wearable biosensor technology for ambulatory cardiac monitoring. The company says the deal broadens its portfolio and addressable market and is expected to enhance its revenue growth rate beginning in 2027 while preserving its 15% adjusted EBITDA margin target for 2027.
Purchase consideration was $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet, plus up to 423,334 shares issued at closing.
iRhythm provided $10.0 million of working capital funding to VitalConnect between signing and closing.
iRhythm will provide updated 2026 financial guidance, inclusive of VitalConnect, on its third quarter earnings call on November 5, 2026.
iRhythm Holdings disclosed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired at 11:59 p.m. Eastern Time on September 18, 2026, for its previously announced merger with Vital Connect, Inc. The company now expects the acquisition to close in early October 2026, subject to customary closing conditions, which clears a regulatory step before completion.
HSR waiting period expired at 11:59 p.m. Eastern Time on September 18, 2026.
Acquisition of Vital Connect, Inc. is anticipated to close in early October 2026.
Closing remains subject to satisfaction or waiver of customary closing conditions.
Merger agreement was entered into on August 5, 2026, with Fortis Advisors LLC representing Vital Connect stockholders.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every iRhythm Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →